Increasing body mass index (BMI), male sex, and certain comorbidities are factors associated with an elevated risk of opioid use in patients with migraine, according to results from the CaMEO* study presented at the recent American Headache Society conference (AHS 2019).
A history of migraine does not appear to affect the risk of cardiovascular disease (CVD) in postmenopausal women, a large observational study presented at the American Headache Society conference (AHS 2019) showed.
Atogepant, a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist, has shown potential in prevention of migraine at a range of doses, according to a presentation at the recent American Headache Society conference (AHS 2019).
Treatment with onabotulinumtoxinA significantly improves headache-related outcomes in patients with chronic migraine (CM) regardless of their response status, according to a study presented at AHS 2019.
Patients receiving topiramate to prevent chronic migraines could potentially switch to onabotulinumtoxinA injections to reduce the frequency of their headaches, according to results of the FORWARD* study presented at the recent American Headache Society conference (AHS 2019).
Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, significantly reduces the number of migraine days in patients with chronic migraine (CM) or episodic migraine (EM), according to the FOCUS* study presented at AHS 2019.
Incorporating yoga as a complementary therapy to standard pharmacological treatment of migraine helps reduce the frequency and intensity of migraine and its impact on the lives of people with such condition, according to the CONTAIN* study presented at the 2019 AHS Meeting.
The novel small-molecule CGRP* receptor inhibitor ubrogepant was effective in relieving migraine pain and resolving the most bothersome migraine-associated symptom (MBS) regardless of prior triptan treatment, including in patients in whom triptans were ineffective, according to a pooled analysis of ACHIEVE I and II studies presented at AHS 2019.
The small-molecule CGRP* receptor inhibitor rimegepant in orally disintegrating tablet (ODT) formulation provides rapid and sustained relief from an acute migraine attack with no safety concerns compared with placebo, according to a study presented at the recent AHS 2019 Meeting.
The efficacy and safety of the two-bag (TB) system are comparable to those of the one-bag (OB) system in adults with diabetic ketoacidosis (DKA), results of a study have shown. Both approaches can be considered in adult DKA patients.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.